Log in

MEI Pharma Stock Price, News & Analysis (NASDAQ:MEIP)

$1.78
-0.01 (-0.56 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$1.74
Now: $1.78
$1.80
50-Day Range
$1.62
MA: $1.78
$2.01
52-Week Range
$1.44
Now: $1.78
$4.05
Volume196,799 shs
Average Volume246,806 shs
Market Capitalization$126.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEIP
Previous SymbolNASDAQ:MSHL
CUSIPN/A
Phone858-369-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.91 million
Book Value$0.67 per share

Profitability

Net Income$-16,820,000.00
Net Margins-819.04%

Miscellaneous

Employees32
Market Cap$126.90 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.


MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) posted its earnings results on Wednesday, August, 28th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.18. The company earned $1.13 million during the quarter, compared to analyst estimates of $1.05 million. MEI Pharma had a negative return on equity of 76.61% and a negative net margin of 819.04%. View MEI Pharma's Earnings History.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for MEI Pharma.

What price target have analysts set for MEIP?

3 analysts have issued 1 year target prices for MEI Pharma's shares. Their predictions range from $10.00 to $10.00. On average, they expect MEI Pharma's stock price to reach $10.00 in the next year. This suggests a possible upside of 461.8% from the stock's current price. View Analyst Price Targets for MEI Pharma.

What is the consensus analysts' recommendation for MEI Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

What are Wall Street analysts saying about MEI Pharma stock?

Here are some recent quotes from research analysts about MEI Pharma stock:
  • 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (9/3/2019)
  • 2. HC Wainwright analysts commented, "$10 PT ICML data update points to expanded opportunity in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). On the heels of reporting promising data in follicular lymphoma (FL) at ASCO earlier this month, MEI Pharma presented more color on its ongoing Phase 1b study in B-cell lymphomas in an oral presentation at ICML. Herein, we highlight the newly reported 100% objective response rates (ORR) with favorable safety in CLL/ SLL, which we believe may bring PI3K inhibition back in the game in the highly competitive CLL/SLL landscape (discussed below)." (6/24/2019)

Has MEI Pharma been receiving favorable news coverage?

News stories about MEIP stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for MEI Pharma.

Are investors shorting MEI Pharma?

MEI Pharma saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 529,400 shares, a drop of 12.1% from the August 30th total of 602,000 shares. Based on an average daily volume of 304,800 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.9% of the company's stock are short sold. View MEI Pharma's Current Options Chain.

Who are some of MEI Pharma's key competitors?

What other stocks do shareholders of MEI Pharma own?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:
  • Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
  • Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
  • Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
  • Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
  • Mr. David A. Walsey, VP of IR & Corp. Communications

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bailard Inc. (0.24%). Company insiders that own MEI Pharma stock include Charles V Baltic III, Christine Anna White and David M Urso. View Institutional Ownership Trends for MEI Pharma.

Which institutional investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc.. View Insider Buying and Selling for MEI Pharma.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $1.78.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $126.90 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

What is MEI Pharma's official website?

The official website for MEI Pharma is http://www.meipharma.com/.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  514
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel